查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1803122

萎縮性陰道炎治療市場預測（至 2032 年）：按產品、患者細分、治療類型、分銷管道、最終用戶和地區進行的全球分析

Atrophic Vaginitis Treatment Market Forecasts to 2032 - Global Analysis By Product, Patient Demographics, Treatment Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球萎縮性陰道炎治療市場預計在 2025 年價值 16 億美元，到 2032 年將達到 31 億美元，預測期內的複合年成長率為 9.6%。

萎縮性陰道炎治療是指旨在緩解其症狀的治療性介入。萎縮性陰道炎是一種以陰道壁變薄、乾燥和發炎為特徵的疾病，通常是由於停經後雌激素水平下降所致。治療的重點是恢復陰道濕潤度、彈性和pH值平衡，並緩解性交過程中的不適、搔癢、灼熱和疼痛。常見的治療方法包括局部或全身雌激素治療、非荷爾蒙保濕劑和潤滑劑，以及生活方式的改變，例如規律的性生活和骨盆底運動。

人口老化和更年期症狀的日益普遍

隨著預期壽命的延長，越來越多的女性進入停經後，陰道萎縮也隨之增加。人們對更年期健康的認知日益提高，促使女性尋求醫療解決方案來緩解不適並改善生活品質。醫療保健提供者提供針對性的治療方案，推動了更年期相關症狀的廣泛應用。更年期相關症狀的普遍存在，使得對有效且安全的治療方案的需求持續成長。總體而言，人口結構變化和日益增強的健康意識正在穩步推動市場成長。

社會恥辱與尷尬

女性常常不願與醫護人員討論私密健康議題。這種不適感會導致診斷和治療的延誤。社會禁忌限制了人們對疾病的認知，並降低了患者的治療需求。恥辱感和羞恥感降低了行銷和教育工作的有效性。不願就醫直接影響了治療方法的接受度。因此，萎縮性陰道炎治療的市場成長仍然有限。

提高認知和教育

女性越來越意識到萎縮性陰道炎的症狀和長期影響，鼓勵她們及時就醫。健康宣傳活動和教育計畫強調了治療的重要性，並減少了討論陰道健康相關的恥辱感。知識的增加使得人們更容易接受現有的治療方法，包括荷爾蒙療法和非荷爾蒙療法。線上資源和遠端醫療平台使資訊更容易獲取，並增強了患者尋求治療的能力。整體而言，更好的認知和教育直接增加了對有效萎縮性陰道炎治療的需求。

來自替代療法的競爭

自然療法和草藥補充劑在尋求更少副作用的患者中越來越受歡迎。這些替代療法通常對那些偏好整體療法和非藥物療法的消費者更具吸引力。非處方藥的選擇也減少了對處方箋藥的依賴。多樣化的治療方案分散了市場佔有率，並減緩了傳統治療方法的成長。因此，製藥公司在患者保留和市場擴張方面面臨挑戰。

COVID-19的影響

新冠疫情擾亂了萎縮性陰道炎治療市場，限制了患者就診，並延誤了常規婦科護理。供應鏈中斷影響了治療和藥物的可近性。新冠疫情導致醫療資源投入增加，導致萎縮性陰道炎等慢性疾病的關注度下降。雖然遠端醫療的普及在一定程度上緩解了治療延誤，但對於不熟悉數位平台的老年患者來說，障礙依然存在。此外，經濟不確定性影響了消費者對非緊急治療的支出意願。總體而言，市場成長暫時放緩，但隨著醫療服務可近性的恢復，預計將逐步恢復。

預計在預測期內，乳膏和藥膏市場將佔最大佔有率

預計乳膏和軟膏類產品將在預測期內佔據最大的市場佔有率，因為它們可以直接緩解陰道乾燥和刺激，提高患者的舒適度。便捷的使用方式有助於持續使用，並提高治療順從性。種類繁多的雌激素和非雌激素配方為患者提供了更多選擇。良好的治療效果可增強患者的信心並促進需求成長。總體而言，該類產品將透過有效緩解核心症狀來推動市場成長。

預計在預測期內，自我藥療患者群體的複合年成長率最高。

預計在預測期內，自我藥療患者群體將實現最高成長率，這得益於對可及治療需求的不斷成長。他們積極主動的策略加速了產品的採用和市場滲透。外用乳霜、凝膠和陰道保濕劑的普及，促使人們頻繁使用。製藥公司正瞄準這群人，進行宣傳宣傳活動，並採用方便用戶使用的包裝。總體而言，自我治療患者正在為市場基礎的穩定成長和擴張做出貢獻。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療體系和廣泛的保險覆蓋。患者的高度認知和積極主動的婦科護理正在推動對有效治療方法的需求。包括非荷爾蒙療法在內的創新產品的推出正在塑造治療偏好。人口老化趨勢日益普遍，支持市場成長。老牌製藥公司的強大存在確保了研發和分銷的效率。數位健康工具和遠端醫療正在改善患者的就醫機會和依從性。然而，對監管審查和治療成本的擔憂可能會影響採用模式和市場動態。

複合年成長率最高的地區：

預計亞太地區將在預測期內實現最高的複合年成長率，這得益於女性健康意識的提升和醫療基礎設施的完善。文化變革鼓勵更多女性尋求治療，而現代治療方法的普及也推動了相關產品的採用。自我護理產品在新興經濟體中日益流行，製藥公司也正在投資針對特定區域的配方。都市化和網路的普及正在推動病患教育，並提升市場滲透率。然而，農村地區的社會污名化仍然是阻礙治療接受和應用的一大挑戰。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球萎縮性陰道炎治療市場（按產品）

  • 乳膏和藥膏
  • 栓劑
  • 片劑和膠囊
  • 陰道環
  • 經皮吸收貼片
  • 其他產品

6. 全球萎縮性陰道炎治療市場（依患者細分）

  • 停經後婦女
  • 圍絕經期婦女
  • 接受過手術閉經的女性

7. 全球萎縮性陰道炎治療市場（依治療類型）

  • 荷爾蒙療法
    • 雌激素治療
    • 生物荷爾蒙療法
  • 非荷爾蒙療法
    • 陰道保濕劑
    • 水性潤滑劑
    • 草藥和天然療法

8. 全球萎縮性陰道炎治療市場（按分銷管道）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

9. 全球萎縮性陰道炎治療市場（依最終用戶）

  • 婦科醫生
  • 全科醫生
  • 病人
  • 其他最終用戶

第10章全球萎縮性陰道炎治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Pfizer Inc.
  • Bayer AG
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Organon & Co.
  • Mylan NV
  • Endo International plc
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Lupin Limited
  • Cipla Ltd.
  • Astellas Pharma Inc.
  • Sanofi SA
  • Novartis AG
Product Code: SMRC30647

According to Stratistics MRC, the Global Atrophic Vaginitis Treatment Market is accounted for $1.6 billion in 2025 and is expected to reach $3.1 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Atrophic vaginitis treatment refers to medical and therapeutic interventions aimed at relieving the symptoms of atrophic vaginitis, a condition characterized by thinning, drying, and inflammation of the vaginal walls, typically due to decreased estrogen levels during menopause or post menopause. Treatments focus on restoring vaginal moisture, elasticity, and pH balance, while alleviating discomfort, itching, burning, and pain during intercourse. Common approaches include local or systemic estrogenic therapy, non-hormonal moisturizers and lubricants, and lifestyle modifications such as regular sexual activity or pelvic floor exercises.

Market Dynamics:

Driver:

Aging population and increased menopause prevalence

Longer life expectancy leads to more women living through post menopause, where vaginal atrophy is more prevalent. Increased awareness about menopausal health encourages women to seek medical solutions for discomfort and quality-of-life improvement. Healthcare providers are offering targeted therapies, boosting treatment adoption. The growing prevalence of menopause-related symptoms creates consistent demand for effective and safe treatment options. Overall, demographic shifts and heightened health consciousness propel market growth steadily.

Restraint:

Social stigma and embarrassment

Women often experience discomfort discussing intimate health issues with healthcare providers. Such discomfort causes delayed diagnosis and treatment. Societal taboos limit awareness, reducing patient demand for therapies. Stigma and embarrassment make marketing and educational efforts less effective. Reluctance to seek care directly impacts therapy adoption rates. Consequently, market growth for atrophic vaginitis treatments remains restricted.

Opportunity:

Growing awareness and education

Women are increasingly recognizing the symptoms and long-term effects of atrophic vaginitis, prompting timely medical consultations. Health campaigns and educational programs emphasize the importance of treatment, reducing stigma around discussing vaginal health. Increased knowledge leads to higher acceptance of available therapies, including hormonal and non-hormonal options. Online resources and telemedicine platforms make information more accessible, empowering patients to seek treatment. Overall, better awareness and education directly boost demand for effective atrophic vaginitis treatments.

Threat:

Competition from alternative therapies

Natural remedies and herbal supplements are gaining popularity among patients seeking fewer side effects. These alternatives often attract consumers who prefer holistic or non-pharmaceutical approaches. Over-the-counter options also reduce dependency on prescription treatments. The presence of diverse treatment choices divides the market share and slows growth for conventional therapies. As a result, pharmaceutical companies face challenges in patient retention and market expansion.

Covid-19 Impact

The Covid-19 pandemic disrupted the Atrophic Vaginitis Treatment Market by limiting patient visits and delaying routine gynaecological care. Supply chain interruptions affected the availability of treatments and medications. Heightened focus on healthcare resources for Covid-19 led to reduced attention on chronic conditions like atrophic vaginitis. Telemedicine adoption partially mitigated treatment delays, but barriers remained for older patients less familiar with digital platforms. Additionally, economic uncertainty impacted consumers' willingness to spend on non-urgent therapies. Overall, market growth slowed temporarily, with gradual recovery expected as healthcare access normalizes.

The creams & ointments segment is expected to be the largest during the forecast period

The creams & ointments segment is expected to account for the largest market share during the forecast period as they provide direct relief of vaginal dryness and irritation, improving patient comfort. Easy application encourages consistent use, boosting treatment adherence. Wide availability of estrogen and non-estrogen formulations expands patient options. Positive treatment outcomes increase patient trust and demand. Overall, this segment drives market growth by addressing core symptoms effectively.

The self-medicating patients' segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the self-medicating patients' segment is predicted to witness the highest growth rate, due to increasing demand for accessible treatments. Their proactive approach accelerates product adoption and market penetration. Easy availability of topical creams, gels, and vaginal moisturizers encourages frequent use. Pharmaceutical companies target this segment with awareness campaigns and user-friendly packaging. Overall, self-medicating patients contribute to steady growth and wider reach of the market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advanced healthcare systems and widespread insurance coverage. High patient awareness and proactive gynaecological care drive demand for effective therapies. Innovative product launches, including non-hormonal options, are shaping treatment preferences. Aging population trends increase prevalence, supporting market growth. Strong presence of established pharmaceutical companies ensures research, development, and distribution efficiency. Digital health tools and telemedicine are improving patient access and compliance. Nevertheless, regulatory scrutiny and treatment cost concerns can influence adoption patterns and market dynamics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to rising awareness of women's health and increasing healthcare infrastructure. Cultural shifts are encouraging more women to seek treatment, while the availability of modern therapies enhances adoption. Emerging economies are witnessing growth in self-care products, and pharmaceutical companies are investing in region-specific formulations. Urbanization and increased internet penetration facilitate patient education, boosting market penetration. However, social stigma in rural areas continues to pose challenges to treatment acceptance and outreach.

Key players in the market

Some of the key players profiled in the Atrophic Vaginitis Treatment Market include Pfizer Inc., Bayer AG, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co., Inc., Amgen Inc., Eli Lilly and Company, Organon & Co., Mylan N.V., Endo International plc, Ferring Pharmaceuticals, Glenmark Pharmaceuticals, Lupin Limited, Cipla Ltd., Astellas Pharma Inc., Sanofi S.A. and Novartis AG.

Key Developments:

In June 2024, Pfizer entered a strategic alliance with Flagship Pioneering to co-develop up to 10 single-asset drug programs. While not exclusively focused on atrophic vaginitis, the model is designed to accelerate R&D in areas including internal medicine and women's health.

In January 2024, Novo Holdings acquired CDMO Catalent for $16.5 billion. Three fill-finish sites will be transferred to Novo Nordisk for $11 billion. While the deal primarily supports GLP-1 production, it expands manufacturing capacity that could benefit hormone-based therapies like Vagifem(R).

Products Covered:

  • Creams & Ointments
  • Suppositories
  • Tablets & Capsules
  • Intravaginal Rings
  • Transdermal Patches
  • Other Products

Patient Demographics Covered:

  • Postmenopausal Women
  • Perimenopausal Women
  • Women with Surgical Menopause

Treatment Types Covered:

  • Hormonal Treatments
  • Non-Hormonal Treatments

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Gynaecologists
  • General Practitioners
  • Patients
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atrophic Vaginitis Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Creams & Ointments
  • 5.3 Suppositories
  • 5.4 Tablets & Capsules
  • 5.5 Intravaginal Rings
  • 5.6 Transdermal Patches
  • 5.7 Other Products

6 Global Atrophic Vaginitis Treatment Market, By Patient Demographics

  • 6.1 Introduction
  • 6.2 Postmenopausal Women
  • 6.3 Perimenopausal Women
  • 6.4 Women with Surgical Menopause

7 Global Atrophic Vaginitis Treatment Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Hormonal Treatments
    • 7.2.1 Estrogen Therapy
    • 7.2.2 Bioidentical Hormone Therapy
  • 7.3 Non-Hormonal Treatments
    • 7.3.1 Vaginal Moisturizers
    • 7.3.2 Water-Based Lubricants
    • 7.3.3 Herbal & Natural Remedies

8 Global Atrophic Vaginitis Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Atrophic Vaginitis Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Gynecologists
  • 9.3 General Practitioners
  • 9.4 Patients
  • 9.5 Other End Users

10 Global Atrophic Vaginitis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Bayer AG
  • 12.3 Novo Nordisk A/S
  • 12.4 Teva Pharmaceutical Industries Ltd.
  • 12.5 AbbVie Inc.
  • 12.6 Merck & Co., Inc.
  • 12.7 Amgen Inc.
  • 12.8 Eli Lilly and Company
  • 12.9 Organon & Co.
  • 12.10 Mylan N.V.
  • 12.11 Endo International plc
  • 12.12 Ferring Pharmaceuticals
  • 12.13 Glenmark Pharmaceuticals
  • 12.14 Lupin Limited
  • 12.15 Cipla Ltd.
  • 12.16 Astellas Pharma Inc.
  • 12.17 Sanofi S.A.
  • 12.18 Novartis AG

List of Tables

  • Table 1 Global Atrophic Vaginitis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Atrophic Vaginitis Treatment Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Atrophic Vaginitis Treatment Market Outlook, By Creams & Ointments (2024-2032) ($MN)
  • Table 4 Global Atrophic Vaginitis Treatment Market Outlook, By Suppositories (2024-2032) ($MN)
  • Table 5 Global Atrophic Vaginitis Treatment Market Outlook, By Tablets & Capsules (2024-2032) ($MN)
  • Table 6 Global Atrophic Vaginitis Treatment Market Outlook, By Intravaginal Rings (2024-2032) ($MN)
  • Table 7 Global Atrophic Vaginitis Treatment Market Outlook, By Transdermal Patches (2024-2032) ($MN)
  • Table 8 Global Atrophic Vaginitis Treatment Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 9 Global Atrophic Vaginitis Treatment Market Outlook, By Patient Demographics (2024-2032) ($MN)
  • Table 10 Global Atrophic Vaginitis Treatment Market Outlook, By Postmenopausal Women (2024-2032) ($MN)
  • Table 11 Global Atrophic Vaginitis Treatment Market Outlook, By Perimenopausal Women (2024-2032) ($MN)
  • Table 12 Global Atrophic Vaginitis Treatment Market Outlook, By Women with Surgical Menopause (2024-2032) ($MN)
  • Table 13 Global Atrophic Vaginitis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 14 Global Atrophic Vaginitis Treatment Market Outlook, By Hormonal Treatments (2024-2032) ($MN)
  • Table 15 Global Atrophic Vaginitis Treatment Market Outlook, By Estrogen Therapy (2024-2032) ($MN)
  • Table 16 Global Atrophic Vaginitis Treatment Market Outlook, By Bioidentical Hormone Therapy (2024-2032) ($MN)
  • Table 17 Global Atrophic Vaginitis Treatment Market Outlook, By Non-Hormonal Treatments (2024-2032) ($MN)
  • Table 18 Global Atrophic Vaginitis Treatment Market Outlook, By Vaginal Moisturizers (2024-2032) ($MN)
  • Table 19 Global Atrophic Vaginitis Treatment Market Outlook, By Water-Based Lubricants (2024-2032) ($MN)
  • Table 20 Global Atrophic Vaginitis Treatment Market Outlook, By Herbal & Natural Remedies (2024-2032) ($MN)
  • Table 21 Global Atrophic Vaginitis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Atrophic Vaginitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 23 Global Atrophic Vaginitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 24 Global Atrophic Vaginitis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 25 Global Atrophic Vaginitis Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Atrophic Vaginitis Treatment Market Outlook, By Gynecologists (2024-2032) ($MN)
  • Table 27 Global Atrophic Vaginitis Treatment Market Outlook, By General Practitioners (2024-2032) ($MN)
  • Table 28 Global Atrophic Vaginitis Treatment Market Outlook, By Patients (2024-2032) ($MN)
  • Table 29 Global Atrophic Vaginitis Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.